<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Data are limited regarding <z:e sem="disease" ids="C0153690" disease_type="Neoplastic Process" abbrv="">bone metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The objective of this study was to survey the natural history of <z:e sem="disease" ids="C0153690" disease_type="Neoplastic Process" abbrv="">bone metastasis</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: This retrospective, multicenter, observational study of 264 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> involving bone examined <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatments, <z:e sem="disease" ids="C0153690" disease_type="Neoplastic Process" abbrv="">bone metastases</z:e> characteristics, skeletal-related event (SRE) type and frequency, <z:chebi fb="0" ids="46557">zoledronic acid</z:chebi> therapy, and disease outcomes </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Most patients with <z:e sem="disease" ids="C0153690" disease_type="Neoplastic Process" abbrv="">bone metastases</z:e> had pathologic T3/4 disease at <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> diagnosis </plain></SENT>
<SENT sid="4" pm="."><plain>The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%) </plain></SENT>
<SENT sid="5" pm="."><plain>Median time from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> diagnosis to <z:e sem="disease" ids="C0153690" disease_type="Neoplastic Process" abbrv="">bone metastases</z:e> was 11.00 months; median time to first SRE thereafter was 2.00 months </plain></SENT>
<SENT sid="6" pm="."><plain>Radiation and <z:hpo ids='HP_0002756'>pathologic fractures</z:hpo> affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs </plain></SENT>
<SENT sid="7" pm="."><plain>Patients survived for a median of 7.00 months after <z:e sem="disease" ids="C0153690" disease_type="Neoplastic Process" abbrv="">bone metastases</z:e> diagnosis; SREs did not significantly affect survival </plain></SENT>
<SENT sid="8" pm="."><plain>Subgroup analyses revealed that <z:chebi fb="0" ids="46557">zoledronic acid</z:chebi> significantly prolonged median time to first SRE (2.00 months versus 1.00 month, respectively, P=0.009) and produced a trend toward improved overall survival versus no <z:chebi fb="0" ids="46557">zoledronic acid</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: This study illustrates the burden of <z:e sem="disease" ids="C0153690" disease_type="Neoplastic Process" abbrv="">bone metastases</z:e> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and supports the use of <z:chebi fb="0" ids="46557">zoledronic acid</z:chebi> in this setting </plain></SENT>
</text></document>